NUVB Overview

Nuvation Bio Inc. is a global oncology company. The Company is focused on tackling cancer treatment. Its diverse pipeline includes taletrectinib (IBTROZI), a next-generation ROS1 inhibitor; safusidenib, a brain-penetrant IDH1 inhibitor, and a drug-drug conjugate (DDC) program. IBTROZI is an oral, potent, central nervous system-active, selective, next-generation ROS1 inhibitor. Safusidenib is a novel, oral, potent, brain penetrant, targeted inhibitor of mutant isocitrate dehydrogenase 1 (mIDH1), which is detected in various tumors, including gliomas. Its platform leverages its drug discovery and chemistry expertise to find the minimum target binding sites of drug X and drug Y and fuse them together, while maintaining activity. Its DDCs are designed to selectively bind to intracellular as well as surface cell membrane targets that are expressed more highly in specific target tissues and to potently deliver anti-cancer warheads to these target tissues.

Wall Street analysts forecast NUVB stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for NUVB is11.38 USD with a low forecast of 8.00 USD and a high forecast of 18.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

Nuvation Bio Inc revenue for the last quarter amounts to 83.23M USD, increased 2598.70

Nuvation Bio Inc. EPS for the last quarter amounts to 0.01 USD, decreased -106.25

Nuvation Bio Inc (NUVB) has 298 emplpoyees as of June 19 2026.

Today NUVB has the market capitalization of 1.94B USD.